Hepatocellular carcinoma: From diagnosis to treatment.
Primary liver cancer is the sixth most common cancer overall and the second most common cause of cancer mortality worldwide. Hepatocellular carcinoma accounts for up to 90% of all primary hepatic malignancies and represents a major international health problem. While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional therapy and sorafenib are beneficial in those with more advanced disease or those who are not surgical candidates. At times, the integration of both surgical and locoregional therapy may be necessary. Hence, hepatocellular carcinoma requires a multidisciplinary approach to determine the most appropriate treatment as well as the timing of various treatments for optimal outcomes.
Department of Surgery, Division of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Miral Sadaria
MS
Grandhi
Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MD, USA.
Amy K
AK
Kim
Department of Surgery, Division of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Sean M
SM
Ronnekleiv-Kelly
Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, MD, USA.
Ihab R
IR
Kamel
Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, MD, USA.
Mounes A
MA
Ghasebeh
Department of Surgery, Division of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA. Electronic address: tpawlik1@jhmi.edu.
Timothy M
TM
Pawlik
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000628:therapy*
Ablation; Functional MRI; Hepatocellular carcinoma; Liver transplantation; Sorafenib; Transarterial chemoembolization (TACE)